Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: Status and clinical potential

Aaron M. Mohs, Zheng Rong Lu

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Blood-pool MRI contrast agents have enormous potential to aid sensitive magnetic resonance detection and yield definitive diagnostic data of cancer and diseases of the cardiovascular system. Many attempts have been initiated to design macromolecular gadolinium (Gd[III]) complexes as magnetic resonance imaging blood-pool contrast agents, as macromolecules do not readily diffuse across healthy vascular endothelium, and remain intravascular. Although extremely efficacious in detecting and characterizing pathologic tissue, clinical development of these agents has been limited by potential toxicity concerns from incomplete Gd(III) clearance. Recent innovative technologies, such as reversible protein-binding contrast agents and biodegradable macromolecular contrast agents, may be valuable alternatives that combine the effective imaging characteristics of an intravascular contrast agent and the safety of clinically approved low-molecular-weight Gd(III) chelates.

Original languageEnglish (US)
Pages (from-to)149-164
Number of pages16
JournalExpert Opinion on Drug Delivery
Volume4
Issue number2
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

Gadolinium
Contrast Media
Magnetic Resonance Imaging
Vascular Endothelium
Cardiovascular System
Protein Binding
Magnetic Resonance Spectroscopy
Molecular Weight
Technology
Safety
Neoplasms

Keywords

  • Blood pool
  • Contrast agent
  • MRI

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging : Status and clinical potential. / Mohs, Aaron M.; Lu, Zheng Rong.

In: Expert Opinion on Drug Delivery, Vol. 4, No. 2, 01.03.2007, p. 149-164.

Research output: Contribution to journalReview article

@article{09a952e4561a4497be034f29a6195913,
title = "Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: Status and clinical potential",
abstract = "Blood-pool MRI contrast agents have enormous potential to aid sensitive magnetic resonance detection and yield definitive diagnostic data of cancer and diseases of the cardiovascular system. Many attempts have been initiated to design macromolecular gadolinium (Gd[III]) complexes as magnetic resonance imaging blood-pool contrast agents, as macromolecules do not readily diffuse across healthy vascular endothelium, and remain intravascular. Although extremely efficacious in detecting and characterizing pathologic tissue, clinical development of these agents has been limited by potential toxicity concerns from incomplete Gd(III) clearance. Recent innovative technologies, such as reversible protein-binding contrast agents and biodegradable macromolecular contrast agents, may be valuable alternatives that combine the effective imaging characteristics of an intravascular contrast agent and the safety of clinically approved low-molecular-weight Gd(III) chelates.",
keywords = "Blood pool, Contrast agent, MRI",
author = "Mohs, {Aaron M.} and Lu, {Zheng Rong}",
year = "2007",
month = "3",
day = "1",
doi = "10.1517/17425247.4.2.149",
language = "English (US)",
volume = "4",
pages = "149--164",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging

T2 - Status and clinical potential

AU - Mohs, Aaron M.

AU - Lu, Zheng Rong

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Blood-pool MRI contrast agents have enormous potential to aid sensitive magnetic resonance detection and yield definitive diagnostic data of cancer and diseases of the cardiovascular system. Many attempts have been initiated to design macromolecular gadolinium (Gd[III]) complexes as magnetic resonance imaging blood-pool contrast agents, as macromolecules do not readily diffuse across healthy vascular endothelium, and remain intravascular. Although extremely efficacious in detecting and characterizing pathologic tissue, clinical development of these agents has been limited by potential toxicity concerns from incomplete Gd(III) clearance. Recent innovative technologies, such as reversible protein-binding contrast agents and biodegradable macromolecular contrast agents, may be valuable alternatives that combine the effective imaging characteristics of an intravascular contrast agent and the safety of clinically approved low-molecular-weight Gd(III) chelates.

AB - Blood-pool MRI contrast agents have enormous potential to aid sensitive magnetic resonance detection and yield definitive diagnostic data of cancer and diseases of the cardiovascular system. Many attempts have been initiated to design macromolecular gadolinium (Gd[III]) complexes as magnetic resonance imaging blood-pool contrast agents, as macromolecules do not readily diffuse across healthy vascular endothelium, and remain intravascular. Although extremely efficacious in detecting and characterizing pathologic tissue, clinical development of these agents has been limited by potential toxicity concerns from incomplete Gd(III) clearance. Recent innovative technologies, such as reversible protein-binding contrast agents and biodegradable macromolecular contrast agents, may be valuable alternatives that combine the effective imaging characteristics of an intravascular contrast agent and the safety of clinically approved low-molecular-weight Gd(III) chelates.

KW - Blood pool

KW - Contrast agent

KW - MRI

UR - http://www.scopus.com/inward/record.url?scp=33847767561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847767561&partnerID=8YFLogxK

U2 - 10.1517/17425247.4.2.149

DO - 10.1517/17425247.4.2.149

M3 - Review article

C2 - 17335412

AN - SCOPUS:33847767561

VL - 4

SP - 149

EP - 164

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 2

ER -